Raltegravir: First in class HIV integrase inhibitor

Zelalem Temesgen, Dawd S. Siraj

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most common adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases and creatine phosphokinase.

Original languageEnglish (US)
Pages (from-to)493-500
Number of pages8
JournalTherapeutics and Clinical Risk Management
Issue number2
StatePublished - May 27 2008


  • Antiretroviral agents
  • HIV
  • Integrase inhibitors
  • Ralteravir

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety


Dive into the research topics of 'Raltegravir: First in class HIV integrase inhibitor'. Together they form a unique fingerprint.

Cite this